Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The increasing rates of resistance to antibiotics among gram-negative pathogens have driven the development of antibiotics that target specific mechanisms of resistance and/or bacterial species. However, due to the potency and price of these drugs, access to them frequently requires prior bacterial identification and susceptibility testing. Until recently, those procedures would require several days, delaying the time to effective therapy. However, new technologies developed or in development by Bruker, bioMérieux, T2 Biosystems, and others now allow for a significant reduction in the turnaround period and facilitate faster and more appropriate antibiotic prescribing. As a consequence, these tools offer the potential to improve outcomes and decrease the overall cost of treatment.
DRG’s Special Topics reports use quantitative and quantitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report on GNIs will help antibiotic and medical device developers understand current and future practices in the clinical microbiology laboratory and how they shape the uptake of current and emerging therapies.
Survey of 100 infectious diseases specialists; more than 10 interviews with thought-leading infectious diseases specialists and medical directors/directors of clinical microbiology laboratories.
KEY DRUGS COVERED
Avycaz, Zerbaxa, Vabomere, Teflaro, and other key GNI generic drugs.
KEY DIAGNOSTICS COVERED
Accelerate Pheno System, fluorescence based assays, MALDI-TOF-MS, and molecular diagnostics.
KEY INSIGHTS PROVIDED
Already a Client? Log in to access this report.
Nuno T. Antunes, , is senior business insights analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in antibacterial agents. Previously, he was a Latin America Market Access senior analyst in the Global Market Access Insights Team, where he developed expertise in market access, pricing and reimbursement, health technology assessment, and health policy. Nuno holds a in animal health from the Universidad de las Palmas de Gran Canaria, Spain, and a degree from the Universidade de Trás-os-Montes e Alto Douro, Portugal. Prior to joining DRG, he conducted research in antimicrobial resistance and antimicrobial development, and worked in the medical devices industry as a scientist.